Targeting NAD metabolism to ameliorate bacterial endophthalmitis

靶向 NAD 代谢改善细菌性眼内炎

基本信息

  • 批准号:
    10621770
  • 负责人:
  • 金额:
    $ 35.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-04-01 至 2027-03-31
  • 项目状态:
    未结题

项目摘要

Project Summary Bacterial endophthalmitis is a vision-threatening complication commonly occurring post penetrating eye injuries and ocular surgeries. Despite aggressive antibiotics and surgical interventions, endophthalmitis often results in partial or complete vision loss. The long-term goal of our research has been to study the pathobiology of endophthalmitis and identify potential therapeutic targets for treatment. In our recent study (PMID: 34095879), using transcriptomics and untargeted metabolomics, we identified several key pathways related to energy metabolism being perturbed during Staphylococcus aureus (SA) endophthalmitis. Among these pathways, we found that bacterial infection rapidly depletes the nicotinamide adenine dinucleotide (NAD+) pool in the mouse retina. NAD+ is not only crucial for oxidation-reduction reactions in the mitochondria, but metabolites of the NAD+ pathway also serve as substrates for various enzymes (e.g., PARPs, sirtuins, and CD38) to maintain cellular homeostasis. Thus, dysregulation in NAD+ metabolism has emerged as a contributing factor in the pathogenesis of several diseases. However, its role has not been investigated in ocular infections. Here, we propose that NAD+ depletion causes bioenergetics collapse, leading to the activation of receptor-interacting protein kinase-3 (RIPK3) mediated retinal cell death. In support, our preliminary data show disruption of the NAD+ synthesis via salvage pathway, increased activity of CD38 NADase, and the activation of RIPK3/MLKL signaling in SA-infected retina and cultured cells. Using a combination of mouse genetic tools, gene therapy, and pharmacological interventions, we will determine mechanisms of NAD+ depletion and restoration of salvage pathway (Aim 1), elucidate the crosstalk between CD38 NADase activity and RIPK3 in regulating retinal cell death (Aim 2), and test the hypothesis whether supplementation of NAD+ precursors can be used as an adjunct therapy to treat bacterial endophthalmitis (Aim 3). Collectively, the mechanistic insights on NAD+ dysregulation and NAD+ supplementation treatment strategies developed in this proposal could have a major impact in the field, not only with regards to ocular infections but other systemic infectious diseases as well.
项目摘要 细菌性眼内炎是眼球穿通伤后常见的一种威胁视力的并发症。 还有眼科手术。尽管有积极的抗生素和手术干预,但眼内炎往往会导致 部分或完全失明。我们研究的长期目标一直是研究肺炎的病理生物学。 眼内炎和确定潜在的治疗靶点。在我们最近的研究中(PMID:34095879), 利用转录组学和非靶向代谢组学,我们确定了几条与能量有关的关键途径 金黄色葡萄球菌(SA)眼内炎期间代谢受扰。在这些途径中,我们 发现细菌感染会迅速耗尽小鼠体内的烟酰胺腺嘌呤二核苷酸(NAD+)池 视网膜。NAD+不仅对线粒体的氧化还原反应至关重要,而且是NAD+的代谢物 途径也是各种酶(如PAPS、sirtuins和CD38)的底物,以维持细胞 动态平衡。因此,NAD+代谢失调已成为发病机制中的一个重要因素。 几种疾病的症状。然而,它在眼部感染中的作用还没有被研究。在此,我们建议NAD+ 耗竭导致生物能量学崩溃,导致受体相互作用的蛋白激酶-3激活。 (RIPK3)介导视网膜细胞死亡。作为支持,我们的初步数据显示,NAD+合成通过 SA感染中抢救途径、CD38NADase活性升高及RIPK3/MLKL信号的激活 视网膜和培养的细胞。使用小鼠遗传工具、基因治疗和药理学的组合 干预,我们将确定NAD+耗尽和恢复抢救途径的机制(目标1), 阐明CD38NADase活性和RIPK3在调节视网膜细胞死亡中的相互作用(目标2),以及 验证补充NAD+前体是否可作为辅助治疗的假说 细菌性眼内炎(目标3)。总而言之,关于NAD+调控失调和NAD+的机械论见解 这项建议中制定的补充治疗战略可能在该领域产生重大影响,不仅是 关于眼部感染,但也包括其他系统性传染病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ashok Kumar其他文献

Ashok Kumar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ashok Kumar', 18)}}的其他基金

ADAR1-mediated antiviral response in Zika virus (ZIKV) infection
ADAR1 介导的寨卡病毒 (ZIKV) 感染抗病毒反应
  • 批准号:
    10621913
  • 财政年份:
    2022
  • 资助金额:
    $ 35.07万
  • 项目类别:
ADAR1-mediated antiviral response in Zika virus (ZIKV) infection
ADAR1 介导的寨卡病毒 (ZIKV) 感染抗病毒反应
  • 批准号:
    10373627
  • 财政年份:
    2022
  • 资助金额:
    $ 35.07万
  • 项目类别:
Age-associated impaired executive function: Rescue by NMDA receptor upregulation
与年龄相关的执行功能受损:通过 NMDA 受体上调来挽救
  • 批准号:
    10033493
  • 财政年份:
    2020
  • 资助金额:
    $ 35.07万
  • 项目类别:
Role of ABCG1 in Zika virus induced chorioretinal atrophy
ABCG1 在寨卡病毒诱导的脉络膜视网膜萎缩中的作用
  • 批准号:
    9436896
  • 财政年份:
    2018
  • 资助金额:
    $ 35.07万
  • 项目类别:
Role of AMP-activated protein kinase in bacterial endophthalmitis - Diversity Supplement
AMP 激活蛋白激酶在细菌性眼内炎中的作用 - Diversity Supplement
  • 批准号:
    10206590
  • 财政年份:
    2017
  • 资助金额:
    $ 35.07万
  • 项目类别:
Role of AMP-activated protein kinase in bacterial endophthalmitis
AMP 激活蛋白激酶在细菌性眼内炎中的作用
  • 批准号:
    9899998
  • 财政年份:
    2017
  • 资助金额:
    $ 35.07万
  • 项目类别:
Targeting NAD metabolism to ameliorate bacterial endophthalmitis
靶向 NAD 代谢改善细菌性眼内炎
  • 批准号:
    10445516
  • 财政年份:
    2017
  • 资助金额:
    $ 35.07万
  • 项目类别:
Mechanisms of Inflammation Resolution in Bacterial Endophthalmitis
细菌性眼内炎的炎症消退机制
  • 批准号:
    10231125
  • 财政年份:
    2017
  • 资助金额:
    $ 35.07万
  • 项目类别:
Mechanisms of Inflammation Resolution in Bacterial Endophthalmitis
细菌性眼内炎的炎症消退机制
  • 批准号:
    10002232
  • 财政年份:
    2017
  • 资助金额:
    $ 35.07万
  • 项目类别:
Toll-like receptors and bacterial endophthalmitis
Toll样受体与细菌性眼内炎
  • 批准号:
    8387011
  • 财政年份:
    2010
  • 资助金额:
    $ 35.07万
  • 项目类别:

相似海外基金

New roles of IFN-inducible OAS proteins in innate immune defense against bacterial infections
IFN诱导的OAS蛋白在针对细菌感染的先天免疫防御中的新作用
  • 批准号:
    10649771
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
Derivation and validation of a clinical prediction rule to identify febrile infants 61 to 90 days old at low and non-negligible risk of invasive bacterial infections
推导和验证临床预测规则,以识别 61 至 90 天大的发热婴儿,其侵袭性细菌感染的风险较低且不可忽略
  • 批准号:
    10574286
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
Structural and functional studies of YbtPQ for fighting bacterial infections
YbtPQ 对抗细菌感染的结构和功能研究
  • 批准号:
    10644889
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
A gut feeling: How can gastrointestinal bacterial infections alter female reproductive tract immunity and control of sexually transmitted infections
直觉:胃肠道细菌感染如何改变女性生殖道免疫力和性传播感染的控制
  • 批准号:
    MR/X031993/1
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
    Research Grant
Molecular probes to diagnose pathoadapatations in bacterial infections
诊断细菌感染病理适应的分子探针
  • 批准号:
    EP/X014479/1
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
    Research Grant
Using Small Area Variation Analysis to Investigate Sources of Practice Variation for Febrile Infants at Risk for Invasive Bacterial Infections
使用小面积变异分析来调查有侵袭性细菌感染风险的发热婴儿的实践变异来源
  • 批准号:
    10588846
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
  • 批准号:
    10549640
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
  • 批准号:
    2306943
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
    Standard Grant
SimCell vaccines against Staphylococcus aureus bacterial infections
针对金黄色葡萄球菌细菌感染的 SimCell 疫苗
  • 批准号:
    10073241
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
    Grant for R&D
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
宿主定向 Orynotide 用于治疗耐多药革兰氏阴性细菌感染
  • 批准号:
    10674221
  • 财政年份:
    2023
  • 资助金额:
    $ 35.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了